• Biosimilars
  • Drug Development/R&D
  • All Topics
OHE OHE
Newsletter SignupSubscribe

News & Insights
  • News
  • Events
  • Insights
  • Bulletin
  • News
  • Events
  • Insights
  • Bulletin

News & Insights

  • News
  • Events
  • Insights
  • Bulletin
Newsletter SignupSubscribe
  • News
  • Events
  • Insights
  • Bulletin

Close
OHE OHE
  • Research & Publications
  • News & Insights
  • Education
  • Innovation Policy Prize
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe

Research & Publications

All Publications

Filter by:
  • Antimicrobial Resistance (AMR)
  • Biosimilars
  • Cell and Gene Therapies
  • Chronic Diseases
  • Combination Therapies
  • COVID-19 Research
  • Digital Health
  • Drug Development/R&D
  • Emerging Markets
  • EQ-5D and PROMs
  • Health Care Systems
  • Health Data and Statistics
  • Health Technology Assessment
  • Precision Medicine
  • Real World Evidence
  • Use of Medicines
  • Value-Based Pricing
  • Vaccine Research
  • Economics of Innovation
  • Measuring and Valuing Outcomes
  • Policy, Organisation and Incentives in Health Systems
  • Value, Affordability and Decision Making

News & Insights

  • News
  • Events
  • Insights
  • Bulletin

Education

  • Education Hub
  • OHE Graduate School
  • EVIA Programme

Innovation Policy Prize

  • The Prize Fund
  • 2022 Prize Fund

Latest Research & Publications

Proposal for a General Outcome-based Value Attribution Framework for Combination Therapies

CombTher_Adobe_photoguns_portrait
Read more
© photoguns
  • Digital Health

Navigating the Landscape of Digital Health – United Kingdom

Healthcare_Adobe_elenabsl
Read more

2021 OHE Annual Report to the Charity Commission

charityreport_lina-trochez-unsplash_landscape
Read more
© Lina Trochez/Unsplash

Supporting the Era of Green Pharmaceuticals in the UK

Sustainability_AdobeStock_270582392_landscape
Read more

Quality of life and wellbeing in individuals with experience of fertility problems and assisted reproductive techniques

Quality of life assisted reproduction Cover
Read more
  • Cell and Gene Therapies
  • Value, Affordability, and…

Health Technology Assessment of Gene Therapies: Are Our Methods Fit for Purpose?

gene_therapies_national-cancer-institute-unsplash_landscape
Read more
© NCI/Unsplash
  • Drug Development/R&D
  • Economics of Innovation
  • Health Policy and Regulation

Limitations of CBO’s Simulation Model of New Drug Development as a Tool for Policymakers

CBO-US_mayer-tawfik-K4Ckc0AxgDI-unsplash_landscape
Read more
© Mayer Tawfik/Unsplash
  • Measuring and Valuing Outcomes

When Generic Measures Fail to Reflect What Matters to Patients: Three Case Studies

PROMS_unsplash_National Cancer Institute_landscape
Read more
© NCI/Unsplash
Close
OHE
  • All Publications

    Filter by:
    • Antimicrobial Resistance (AMR)
    • Biosimilars
    • Cell and Gene Therapies
    • Chronic Diseases
    • Combination Therapies
    • COVID-19 Research
    • Digital Health
    • Drug Development/R&D
    • Emerging Markets
    • EQ-5D and PROMs
    • Health Care Systems
    • Health Data and Statistics
    • Health Technology Assessment
    • Precision Medicine
    • Real World Evidence
    • Use of Medicines
    • Value-Based Pricing
    • Vaccine Research
    • Economics of Innovation
    • Measuring and Valuing Outcomes
    • Policy, Organisation and Incentives in Health Systems
    • Value, Affordability and Decision Making
    • News
    • Events
    • Insights
    • Bulletin
    • Education Hub
    • OHE Graduate School
    • EVIA Programme
    • The Prize Fund
    • 2022 Prize Fund
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe
Back
  • Insight
11 min read 29th March 2021

Time to Tackle the Challenges around Combination Therapies for Cancer

A new Editorial reviews three solutions to the price and value challenge to reimbursing combination products. Higher thresholds are not justifiable. Evidence to support use of shorter regimens will take time to develop. Multi-use pricing is the best option to…

Share:
  •  Twitter
  •  LinkedIn
  •  Facebook
  • has-icon Email

A new Editorial reviews three solutions to the price and value challenge to reimbursing combination products. Higher thresholds are not justifiable. Evidence to support use of shorter regimens will take time to develop. Multi-use pricing is the best option to explore.

A new Editorial reviews three solutions to the price and value challenge to reimbursing combination products. Higher thresholds are not justifiable. Evidence to support the use of shorter regimens will take time to develop. Multi-use pricing is the best option to explore.

It is eight years since NICE suggested pertuzumab, when used in combination with trastuzumab and docetaxel for the treatment of HER2 positive breast cancer, might not be cost-effective, even if pertuzumab were offered at zero price. It is seven years since the NICE Decision Support Unit published analysis of how this counter-intuitive situation arises.  Combination therapies continue to come to market, often at prices presenting challenges to payers around the world. Indeed, experts agree combination therapies will become increasingly important in oncology.

A new Editorial, Not Cost-effective at Zero Price, in Expert Review of Pharmacoeconomics and Outcomes Research, sets out a broad framework for action. It builds on a workshop held in November 2019 in Australia by the not-for-profit Bellberry organisation, with invited stakeholders from around the world.  A report of the workshop was published in May 2020.

The authors, Nick Latimer, University of Sheffield, and OHE’s Adrian Towse and Chris Henshall, explain that the problem arises when the ‘backbone’ oncology drug is priced at the limit of what a payer is prepared to pay given the outcomes delivered. Willingness to pay for a new ‘add-on’ drug to backbone therapy will be limited to the additional benefit.  If the combination involves extended duration of treatment using the backbone (as with pertuzumab) as well as other extra costs, then no price may be low enough, let alone the price being sought by the developer. These challenges arise in all situations where coverage and price are linked systematically to the assessment of benefit (and not just where QALYs are used).

Three possible solutions are discussed:

1. Increase the willingness to pay for combination therapies in oncology, over and above that for monotherapy drugs. This is not supported by evidence of public or stakeholder preferences;

2. Improve the outcomes achieved by new combinations,  improving clinical development to identify optimum treatment paradigms (such as treatment durations and stopping rules that optimise health benefits and minimise adverse effects and costs). This is important but challenging. Significant progress seems unlikely in the short term;

3. Adjust the price of both constituents of a combination to reflect the value they offer when used in that combination.  This is the most feasible way forward to address the challenges of combination therapies in the near future.

Progress depends upon finding ways of aligning individual drug prices with the value attributable to them in that combination – which may be different from the value in monotherapy use or in another combination.  Where these drugs are made by the same manufacturer, it can agree to price variations with a payer to achieve this. But, usually, different manufacturers are involved and some form of explicit multi-use pricing is required. This in turn needs some way of agreeing on the value – and therefore the price – of each use.

The authors recognise the challenges in making multi-use pricing work, but conclude that it would be both beneficial and feasible for combination therapies. They go on to discuss how the value and price of each component within a combination could be determined.  Various methods have been suggested for value attribution, and work is needed to develop and assess these. But while an agreed approach to value attribution could help, the authors see the negotiation and agreement of prices as the biggest challenge. Ways need to be found to agree on prices for components from different manufacturers that add up to no more than the value-based price of the combination.  Issues to be addressed here include the role that an HTA or Payer body could and should play in instigating or joining negotiations between manufacturers, and the ways in which such negotiations could be conducted without contravening competition law.    

Where to next? A number of researchers are working on methods to attribute value to individual components in a combination.  A recent OHE/Amgen paper on this was described in an OHE blog, and a paper is expected soon from a Takeda sponsored group looking at solutions in England.

Competition law differs by country, but usually bans companies who are competitors from discussing pricing with each other. Mechanisms are therefore needed to enable companies to negotiate prices with each other that are legal within particular jurisdictions.  The Takeda sponsored group will publish a possible approach to negotiation in England.  Hopefully, this will stimulate similar work in other systems. For example, a trading platform has been proposed.

A number of assessment and payer bodies around the world are still not yet formally engaged. We believe there is a strong case for meetings involving key stakeholders in Europe, the USA, and Asia to discuss the challenges and share ideas for, and practical experience with, solutions.

Citation

Latimer, N.R., Towse A. and Henshall C. (2021): Not cost effective at zero price: valuing and paying for combination therapies in cancer, Expert Review of Pharmacoeconomics & Outcomes Research, DOI: 10.1080/14737167.2021.1879644. Available at https://doi.org/10.1080/14737167.2021.1879644  

Related Research

Towse, A., Lothgren, M., Steuten, L., and Bruce, A., 2021. Why we need a new Outcomes-based Value Attribution Framework for Combination Regimens in Oncology. OHE Consulting Report, London: Office of Health Economics. Available at: https://www.ohe.org/publications/why-we-need-new-outcomes-bashttps://www.ohe.org/publications/why-we-need-new-outcomes-based-value-attribution-framework-combination-regimensed-value-at…

Latimer N, Pollard D, Towse A, Henshall C. 2020. Challenges in valuing and paying for combination regimens in oncology. Report of an international workshop convened by Bellberry, held on November 18-20, in Sydney, Australia. May 2020. Available at https://bellberry.com.au/wp-content/uploads/Meeting-report-final-draft-May-2020.pdf

 

 

 

  • Value-Based Pricing
  • Economics of Innovation
  • Amgen

Related Insights

Fishing on the lake at sunset. Fishing background.
  • Insight
  • February 2023

Fishing for Innovative Drugs with the ODRS: Potential Benefits and Challenges

Read more
Cancer_WellcomeCollection_landscape
  • Insight
  • January 2023

Combination Therapies: A Step Forward to the Value Attribution Problem

Read more
G7Antibiotics_blog_featuredimage
  • Insight
  • December 2022

G7 Investments in New Antibiotics Would Pay Off – For Everyone

Read more
Slide3
  • Insight
  • October 2022

The Economics of Antibiotics – Part 3: Creating a Healthy Global Market for New Antibiotics

Read more
footer_ohe_logo

Leading intellectual authority on global health economics

Sign Up for the OHE News Bulletin

Newsletter SignupStart Sign Up

Research & Publications

News & Insights

Innovation Policy Prize

Education

Events

About Us

OHE Experts

Contact Us

Sign Up for the OHE News Bulletin

Newsletter SignupStart Sign Up

The Office of Health Economics (OHE) is a company limited by guarantee registered in England and Wales (registered number 09848965) and its registered office is at 2nd Floor Goldings House, Hay’s Galleria, 2 Hay’s Lane, London, SE1 2HB.

Terms & Conditions

Privacy Policy

Cookies Policy

© 2023 Website Design

An error has occurred, please try again later.An error has occurred, please try again later.

We are using cookies to give you the best experience on our website.

You can find out more about which cookies we are using or switch them off in settings.

 Twitter
 Facebook
 LinkedIn
 Copy
 Email
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.

3rd Party Cookies

This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.

Keeping this cookie enabled helps us to improve our website.

Please enable Strictly Necessary Cookies first so that we can save your preferences!